VA
PCRX icon

Vident Advisory’s Pacira BioSciences PCRX Stock Holding History

Vident Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$771K Buy
34,113
+10,542
+45% +$234K 0.01% 996
2025
Q4 		$610K Buy
23,571
+3,075
+15% +$73.1K 0.01% 1053
2025
Q3 		$528K Buy
20,496
+2,255
+12% +$55.4K 0.01% 1180
2025
Q2 		$436K Sell
18,241
-2,078
-10% -$52.4K ﹤0.01% 1142
2025
Q1 		$505K Sell
20,319
-9,035
-31% -$216K 0.01% 1027
2024
Q4 		$553K Sell
29,354
-1,493
-5% -$26.2K 0.01% 889
2024
Q3 		$464K Buy
+30,847
New +$527K 0.01% 963

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return